Literature DB >> 3847288

Evaluation of in vivo and in vitro effectivity of immune defense against a spontaneously arising, nonlymphoid rat tumor. I. Analysis of natural immune defense.

M Zöller.   

Abstract

Possible mechanisms of natural defense against a nonimmunogenic, nonlymphoid rat tumor were evaluated in vitro and examined for effectivity in vivo, using BSp6S, the subcutaneously grown transplantation line of a spontaneously arising fibrosarcoma in the BDX rat strain, which is highly susceptible to natural killer (NK) cells and macrophages (Mø). The role of nonspecific immune defense in vivo was demonstrated by eliminating NK cells by irradiation and Mø by silica treatment. Especially after depletion of NK cells a significant acceleration of tumor growth and a reduction in the number of cells required for tumor takes was observed. Activation of Mø by Corynebacterium parvum (CP) did lead to retardation of tumor growth; prevention of tumor growth was only achieved after inoculation of a marginal dose of tumor cells. Activation of NK cells was of minor influence. It is concluded that NK cells and Mø are the main influences on survival time, the effectiveness of NK cells being limited to early periods of tumor growth.

Entities:  

Mesh:

Year:  1985        PMID: 3847288     DOI: 10.1007/bf00199224

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  37 in total

1.  A rapid method for the separation of functional lymphoid cell populations of human and animal origin on PVP-silica (Percoll) density gradients.

Authors:  J T Kurnick; L Ostberg; M Stegagno; A K Kimura; A Orn; O Sjöberg
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

2.  Inhibition of the growth of lymphoid tumours in syngeneic athymic (nude) mice.

Authors:  N L Warner; M F Woodruff; R C Burton
Journal:  Int J Cancer       Date:  1977-07-15       Impact factor: 7.396

3.  Immunology of spontaneously arising rat mammary adenocarcinomas.

Authors:  R W Baldwin; M J Embleton
Journal:  Int J Cancer       Date:  1969-07-15       Impact factor: 7.396

4.  Effects of a cloned cell line with NK activity on bone marrow transplants, tumour development and metastasis in vivo.

Authors:  J F Warner; G Dennert
Journal:  Nature       Date:  1982-11-04       Impact factor: 49.962

5.  Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice.

Authors:  K Kärre; G O Klein; R Kiessling; G Klein; J C Roder
Journal:  Nature       Date:  1980-04-17       Impact factor: 49.962

6.  Role of non-conventional natural killer cells in resistance against syngeneic tumour cells in vivo.

Authors:  O Haller; M Hansson; R Kiessling; H Wigzell
Journal:  Nature       Date:  1977-12-15       Impact factor: 49.962

7.  Natural cytotoxicity in lymphatic metastasis. II. In vivo studies with BSp73 variants differing in metastatic capacity.

Authors:  S Matzku
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

8.  In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice.

Authors:  S Habu; H Fukui; K Shimamura; M Kasai; Y Nagai; K Okumura; N Tamaoki
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

9.  Selective depletion of NK cell activity in vivo and its effect on the growth of NK-sensitive and NK-resistant tumor cell variants.

Authors:  I Kawase; D L Urdal; C G Brooks; C S Henney
Journal:  Int J Cancer       Date:  1982-05-15       Impact factor: 7.396

10.  A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin.

Authors:  H B Hewitt; E R Blake; A S Walder
Journal:  Br J Cancer       Date:  1976-03       Impact factor: 7.640

View more
  1 in total

1.  IFN-treatment of B16-F1 versus B16-F10: relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread.

Authors:  M Zöller
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.